Core Insights - OptimizeRx Corp. reported strong financial results for Q4 and full year 2024, exceeding expectations and consensus estimates, with a focus on leveraging its industry leadership to address critical challenges in the pharmaceutical sector [1][5][7] Financial Performance - Q4 revenue reached $32.3 million, a 14% increase year-over-year from $28.4 million in Q4 2023 [4][5] - Full year revenue for 2024 was $92.1 million, representing a 29% increase compared to $71.5 million in 2023 [5][21] - Q4 gross profit increased 23% year-over-year to $22.0 million, with a gross margin of 68% [4][5] - Full year gross profit totaled $59.4 million [5] - Non-GAAP net income for Q4 was $5.5 million, or $0.30 per diluted share, while for the full year it was $6.2 million, or $0.34 per diluted share [5][25] - Adjusted EBITDA for Q4 was $8.8 million, a 53% increase from $5.8 million in Q4 2023 [5][26] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturer increased to $2.933 million in 2024 from $2.399 million in 2023 [2] - Net revenue retention improved to 121% in 2024 from 105% in 2023 [2] - The percentage of total revenue attributable to the top 20 pharmaceutical manufacturers was 64% in 2024, down from 67% in 2023 [2] Strategic Outlook - The company aims to achieve at least $100 million in revenue and an Adjusted EBITDA of at least $12 million for the full year 2025 [7] - A strategic focus on transitioning DAAP customers to a subscription-based model is expected to improve margins and reduce business cyclicality [1][5]

Core Points - OptimizeRx Corp. has received a notice from Whetstone Capital Advisors, LLC regarding the nomination of two candidates for the Board of Directors at the 2025 Annual Meeting of Stockholders [1] - The Board of Directors will provide a formal recommendation on the nominations in the definitive proxy statement to be filed with the SEC [2] Company Overview - OptimizeRx is a leading healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [3] - The company focuses on patient-centric technology, ensuring meaningful interactions that deliver therapies to the right patients at the right time [4] Proxy Statement Information - OptimizeRx plans to file proxy materials with the SEC for the 2025 Annual Meeting, including a definitive proxy statement and a WHITE proxy card [6] - Stockholders are encouraged to read the proxy statement and related documents carefully when available, as they will contain important information [7] Participant Information - The company, its directors, and certain executive officers may be deemed "participants" in the proxy solicitation for the 2025 Annual Meeting [8]

Core Viewpoint - OptimizeRx Corp. has appointed Steve Silvestro as the new Chief Executive Officer, effective March 10, 2025, to lead the company into its next phase of growth and transformation [1][3]. Company Leadership - Steve Silvestro has over 20 years of experience in health technology and services, having joined OptimizeRx in 2019 as Chief Commercial Officer and later serving as President and interim CEO [2][4]. - The Board of Directors conducted a thorough search for the new CEO, resulting in a unanimous decision to appoint Silvestro, who has been pivotal in enhancing the company's brand relevance and capabilities [3]. Strategic Focus - Silvestro aims to differentiate OptimizeRx through technology and strategic partnerships, emphasizing operational excellence and customer satisfaction [3]. - The company has completed a strategic review of its business processes and is focused on increasing recurring revenue and becoming a "Rule of 40" company, which refers to a combined growth and profit margin of 40% [3]. Company Overview - OptimizeRx is a leading healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [5][6]. - The company is headquartered in Waltham, Massachusetts, and partners with major pharmaceutical and life sciences companies to improve healthcare outcomes [6].

Core Viewpoint - OptimizeRx Corp. is set to discuss its full year fiscal 2024 financial results and fourth quarter results on March 12, 2025, indicating a focus on transparency and engagement with investors [1]. Group 1: Conference Call Details - The conference call will take place on March 12, 2025, at 8:30 a.m. Eastern Time [2]. - Participants can join via a toll-free number or an international line, with specific access details provided [2]. - A replay of the call will be available for 12 months on the company's investor relations website [3]. Group 2: Company Overview - OptimizeRx provides innovative technology that enhances engagement between life sciences organizations, healthcare providers, and patients [4]. - The company has the capability to synchronize messaging across 2 million healthcare providers and over 240 million adults through various digital channels [4].

Company Leadership Transition - William J. Febbo, CEO of OptimizeRx, will depart the company effective December 31, 2024, to pursue other opportunities, while providing advisory services until March 31, 2025 [9] - Stephen Silvestro has been appointed as the interim CEO during the search for a new candidate, having previously served as Chief Commercial Officer and President [10] Company Growth and Strategy - OptimizeRx has experienced significant growth under Febbo's leadership, transforming from a single point of care product to an omnichannel platform, and is well-positioned for future growth [1] - The company reaffirms its financial guidance for the full year 2024, expecting to achieve results at the higher end of its revenue and adjusted EBITDA guidance range [2] Company Overview - OptimizeRx provides healthcare technology solutions that facilitate engagement between life sciences organizations, healthcare providers, and patients, connecting over 2 million U.S. healthcare providers through its digital point-of-care network [6]

Group 1: Earnings Performance - OptimizeRx Corp. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.09 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $21.31 million for the quarter ended September 2024, which missed the Zacks Consensus Estimate by 14.55%, compared to year-ago revenues of $16.33 million [2] - Over the last four quarters, OptimizeRx has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Group 2: Stock Performance and Outlook - OptimizeRx shares have declined approximately 59.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $37.55 million, and for the current fiscal year, it is $0.36 on revenues of $93.34 million [7] Group 3: Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact OptimizeRx's stock performance [5]

Financial Performance - Q3 2024 revenue increased by 30% year-over-year to $21.3 million, compared to $16.3 million in Q3 2023[2] - Q3 2024 gross profit rose by 37% year-over-year to $13.4 million, with a gross margin of 63%[1] - Non-GAAP net income for Q3 2024 was $2.3 million, or $0.12 per diluted share, up from $1.6 million or $0.09 per diluted share in Q3 2023[3] - Adjusted EBITDA for Q3 2024 was $2.7 million, compared to $0.9 million in the same period last year[3] - GAAP net loss for Q3 2024 was $(9.1) million, or $(0.50) per share, compared to $(2.9) million or $(0.17) per share in Q3 2023[4] - Net revenue for the three months ended September 30, 2024, was $21,309 thousand, a 30.5% increase from $16,331 thousand for the same period in 2023[24] - Gross profit for the nine months ended September 30, 2024, was $37,355 thousand, up 48.8% from $25,059 thousand in the prior year[24] - The net loss for the three months ended September 30, 2024, was $(9,124) thousand, compared to $(2,865) thousand for the same period in 2023, indicating a significant increase in losses[24] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $16.1 million as of September 30, 2024, up from $13.9 million at the end of 2023[4] - Cash provided by operating activities was $4,691 thousand for the nine months ended September 30, 2024, compared to $(982) thousand in the same period of 2023[25] - Cash and cash equivalents at the end of the period were $16,126 thousand, up from $9,923 thousand at the end of September 2023[25] Debt and Equity - The company has paid down an additional $2.0 million of principal on its term loan since the end of Q3 2024[5] - Total stockholders' equity decreased to $114,465 thousand as of September 30, 2024, down from $126,553 thousand at the end of 2023[22] - The company incurred interest expense of $(1,524) thousand for the three months ended September 30, 2024, with total other income (expense) netting to $(1,379) thousand[24] Revenue Expectations and Retention - The company expects full-year 2024 revenue to be between $88 million and $92 million, with Adjusted EBITDA between $8 million and $10 million[7] - The company achieved a net revenue retention rate of 93% for the top 20 pharmaceutical manufacturers[6] - The average revenue per top 20 pharmaceutical manufacturer decreased to $1.902 million from $2.824 million year-over-year[6] Operating Expenses and Impairments - Operating expenses increased to $54,695 thousand for the nine months ended September 30, 2024, compared to $40,557 thousand in the same period of 2023, representing a 35% rise[24] - The company reported a goodwill impairment of $7,489 thousand for the three months ended September 30, 2024[24] Share Information - The weighted average number of shares outstanding for basic loss per share was 18,323,542 for the three months ended September 30, 2024, compared to 16,637,606 for the same period in 2023[24]

Company Overview - OptimizeRx Corp. (OPRX) shares increased by 19.8% to close at $6.12, following a notable trading volume, contrasting with a 27.4% loss over the past four weeks [1] - The company is experiencing strong growth through its Dynamic Audience Activation Platform, which provides predictive and secure marketing across a network connecting patients, healthcare providers, and the life sciences sector [1] Earnings Expectations - The upcoming quarterly earnings report is expected to show earnings of $0.06 per share, reflecting a year-over-year decrease of 33.3%, while revenues are projected to be $24.94 million, an increase of 52.7% from the previous year [2] - The consensus EPS estimate for OptimizeRx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - OptimizeRx is categorized within the Zacks Computer - Software industry, where Intuit (INTU) also operates, having closed 4.8% higher at $648.39, with a 0.9% return over the past month [3] - Intuit's consensus EPS estimate has seen a slight increase of 0.1% to $2.36, representing a year-over-year change of -4.5%, and currently holds a Zacks Rank of 4 (Sell) [4]

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management wil ...

OptimizeRx Corp. (OPRX) shares soared 5.4% in the last trading session to close at $7.59. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks. The increase in share price can be attributed to higher demand for the company's innovative DAAP (Dynamic Audience Activation Platform) solution. The platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences acr ...